Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Drug Allergy
•
Primary Care
Do you believe that pretreatment with montelukast or other LTRAs can reduce the risk of urticaria or angioedema with NSAIDS?
Related Questions
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
What medications would you have a patient avoid with an IgE mediated reaction to cyclobenzaprine?
Would you proceed to a direct penicillin challenge in a patient with a reaction history 30+ years ago without any further clinical history?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
What is your preferred biologic for an asthmatic patient with a T2 low phenotype and who is a smoker?
Do you continue shots when a patient transfers under your care and has been receiving less than effective doses of AIT, but insist they have been effective?
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
When would you favor initiation of mepolizumab versus dupilumab for CRSwNP?
